Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Low skeletal muscle mass (LSMM) identified via CT scans is a promising biomarker for improved melanoma-specific survival in patients receiving adjuvant immune checkpoint blockade (ICB) therapy. LSMM also correlates with a reduced risk of adverse events from ICB treatment.
Area Of Science
- Oncology
- Radiology
- Immunotherapy
Background
- Adjuvant immune checkpoint blockade (ICB) therapy improves outcomes in melanoma but lacks biomarkers for patient selection.
- Many patients do not benefit from ICB or experience severe adverse events (AEs).
- Body composition analysis, particularly from CT scans, shows potential as a prognostic biomarker in advanced melanoma.
Purpose Of The Study
- To investigate the utility of body composition parameters, specifically low skeletal muscle mass (LSMM), as a biomarker in patients with resected melanoma receiving adjuvant ICB.
- To assess the impact of LSMM on melanoma-specific survival and the occurrence of AEs in this patient cohort.
Main Methods
- Retrospective analysis of 109 patients with resected stage IIB-IV melanoma treated with adjuvant ICB.
- Evaluation of body composition features from CT scans, focusing on LSMM.
- Correlation of LSMM with melanoma-specific survival and therapy-related AEs.
Main Results
- CT-measured LSMM was significantly associated with improved melanoma-specific survival in patients receiving adjuvant ICB.
- LSMM correlated with a lower risk of therapy-related AEs, including hypothyroidism, fatigue, and xerostomia.
- Conventional biomarkers (S100, LDH) and adipose tissue measures did not correlate with survival or AEs.
Conclusions
- Low skeletal muscle mass (LSMM) is a novel and significant biomarker for predicting melanoma-specific survival in patients undergoing adjuvant ICB therapy.
- LSMM may help identify patients likely to benefit from adjuvant ICB and those at lower risk for adverse events.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.